Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20021TZ" target="_blank" >RIV/61988987:17110/19:A20021TZ - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/19:00112506 RIV/00216208:11110/19:10394239 RIV/00216208:11150/19:10394239 RIV/61989592:15110/19:73595637 and 5 more

Result on the web

<a href="https://scholar.google.com/scholar_lookup?author=V%20Maisnar&atitle=Lenalidomide%20and%20dexamethasone%20in%20treatment%20of%20patients%20with%20relapsed%20and%20refractory%20multiple%20myeloma%20-%20analysis%20of%20data%20from%20the%20Czech%20Myeloma%20" target="_blank" >https://scholar.google.com/scholar_lookup?author=V%20Maisnar&atitle=Lenalidomide%20and%20dexamethasone%20in%20treatment%20of%20patients%20with%20relapsed%20and%20refractory%20multiple%20myeloma%20-%20analysis%20of%20data%20from%20the%20Czech%20Myeloma%20</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2018_180824N644" target="_blank" >10.4149/neo_2018_180824N644</a>

Result language

angličtina

Original language name

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Original language description

Lenalidomide (LEN) is an immunomodulator with clinical activity against myeloma cells. Based on the pivotal phase 3 trials MM-009 and MM-010, the combination of lenalidomide and dexamethasone(DEX) was approved for patients with multiple myeloma who received at least one prior therapy. Here, we evaluated LEN/DEX therapy in whole population and subsequently in selected sub-groups of patients with relapsed/refractory multiple myeloma followed in the Monoclonal Gammopathy Registry of the Czech Myeloma Group. 858 patients were treated with LEN/DEX in Czech Republic and Slovakia until end of 2017. The analyzed sub-groups were defined as patients with high-risk cytogenetic aberrations and patients with relapsed and refractory MM. The ORR (response better than PR) in whole group of patients was 46.3% for all lines of therapy, 26.4% for high-risk group and 32.1% for relapsed and refractory group. Overall survivals (OS) in the same sets were as follows: 25.6, 15.7 and 18.5 months respectively, progression free survival (PFS) was 11.2, 6.4 and 9.0 months, respectively. The most common adverse events were hematologic and infectious. In conclusion, we found our results correlated with those in other studies in terms of OS, PFS and also of treatment toxicity.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

NEOPLASMA

ISSN

0028-2685

e-ISSN

1338-4317

Volume of the periodical

66

Issue of the periodical within the volume

3

Country of publishing house

SK - SLOVAKIA

Number of pages

6

Pages from-to

499-505

UT code for WoS article

000491237700020

EID of the result in the Scopus database

—